Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.

Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.

2.

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.

Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R.

BMC Cancer. 2013 Jan 15;13:20. doi: 10.1186/1471-2407-13-20.

3.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL.

Invest New Drugs. 2013 Apr;31(2):399-408. doi: 10.1007/s10637-012-9890-y. Epub 2012 Nov 17.

4.

Viral tropism and pathology associated with viral hemorrhagic septicemia in larval and juvenile Pacific herring.

Lovy J, Lewis NL, Hershberger PK, Bennett W, Meyers TR, Garver KA.

Vet Microbiol. 2012 Dec 28;161(1-2):66-76. doi: 10.1016/j.vetmic.2012.07.020. Epub 2012 Jul 20.

PMID:
22857977
5.

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM, Schwartz GK.

Invest New Drugs. 2013 Apr;31(2):355-62. doi: 10.1007/s10637-012-9821-y. Epub 2012 May 22.

PMID:
22615058
6.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.

Ann Oncol. 2012 May;23(5):1234-40. doi: 10.1093/annonc/mdr399. Epub 2011 Sep 19.

7.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG.

J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4.

8.

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.

Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB.

J Clin Oncol. 2009 Nov 1;27(31):5262-9. doi: 10.1200/JCO.2009.21.8487. Epub 2009 Sep 8.

9.

The effect of stretching on muscle responses and postural sway responses during computerized dynamic posturography in women and men.

Lewis NL, Brismée JM, James CR, Sizer PS, Sawyer SF.

Arch Phys Med Rehabil. 2009 Mar;90(3):454-62. doi: 10.1016/j.apmr.2008.09.570.

PMID:
19254611
10.

Effects of food on the relative bioavailability of lapatinib in cancer patients.

Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, Stead A, Beelen AP, Lewis LD.

J Clin Oncol. 2009 Mar 10;27(8):1191-6. doi: 10.1200/JCO.2008.18.3285. Epub 2009 Feb 2.

11.

Occult primary.

Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W.

J Natl Compr Canc Netw. 2008 Nov;6(10):1026-60. Review. No abstract available.

PMID:
19176200
12.

Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.

Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ.

Am J Clin Oncol. 2008 Feb;31(1):1-5. doi: 10.1097/COC.0b013e31805c142f.

PMID:
18376220
13.

The platelet-derived growth factor receptor as a therapeutic target.

Lewis NL.

Curr Oncol Rep. 2007 Mar;9(2):89-95. Review.

PMID:
17288872
14.

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ.

Clin Colorectal Cancer. 2006 Jul;6(2):125-32.

PMID:
16945168
15.

Survey of training in obstetric general anaesthesia in the UK.

Lewis NL, Plaat F.

Int J Obstet Anesth. 2006 Apr;15(2):175-6. Epub 2006 Feb 20. No abstract available.

PMID:
16488601
16.

Trainees' experiences of difficult and failed intubation in obstetrics.

Lewis NL, Plaat F.

Anaesthesia. 2006 Jan;61(1):69-70. No abstract available.

18.
19.

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ.

Cancer Chemother Pharmacol. 2004 Jun;53(6):513-8. Epub 2004 Feb 3.

PMID:
14760509
20.

Development of new agents for the treatment of advanced colorectal cancer.

Lewis NL, Meropol NJ.

Clin Colorectal Cancer. 2003 Nov;3(3):154-64. Review.

PMID:
14706174

Supplemental Content

Loading ...
Support Center